Cargando…

Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas

Vemurafenib (PLX4032), a selective inhibitor of Braf, has been FDA-approved for the treatment of unresectable or metastatic melanoma in patients with Braf(V600E) mutations. Many patients treated with vemurafenib initially display dramatic improvement, with decreases in both risk of death and tumor p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Fang, Cao, Juxiang, Wu, Jinxiang, Sullivan, Kayleigh, Shen, James, Ryu, Byungwoo, Xu, Zhixiang, Wei, Wenyi, Cui, Rutao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744462/ https://www.ncbi.nlm.nih.gov/pubmed/23344460 http://dx.doi.org/10.1038/jid.2013.32

Ejemplares similares

EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells
por: Laurenzana, Anna, et al.
Publicado: (2019)

Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro
por: Car, Iris, et al.
Publicado: (2023)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway
por: Wang, Lei, et al.
Publicado: (2022)

Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer
por: Wei, Wei-Jun, et al.
Publicado: (2017)

A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib
por: Sinnberg, Tobias, et al.
Publicado: (2016)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023)

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
por: Hernandez-Davies, Jenny E, et al.
Publicado: (2015)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells
por: Delgado-Goñi, Teresa, et al.
Publicado: (2019)

HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma
por: Hüser, Laura, et al.
Publicado: (2020)

Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma
por: Kim, Tae Woo, et al.
Publicado: (2022)

Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing
por: Salton, Maayan, et al.
Publicado: (2015)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells
por: Zhao, Kun, et al.
Publicado: (2020)

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021)

Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo
por: Radi, Rakan, et al.
Publicado: (2022)

Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells
por: Bokharaie, Honey, et al.
Publicado: (2022)

Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells
por: Tabolacci, Claudio, et al.
Publicado: (2022)

3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells
por: Vital, Patrik da Silva, et al.
Publicado: (2022)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets
por: Tóvári, József, et al.
Publicado: (2023)

The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
por: Zhao, Bei, et al.
Publicado: (2018)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
por: Guzzetti, Carlotta, et al.
Publicado: (2023)

Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b
por: Vergani, Elisabetta, et al.
Publicado: (2015)

Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition
por: Singh, Sunanda, et al.
Publicado: (2023)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
por: Hagen, Brenda, et al.
Publicado: (2014)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
por: Osrodek, Marta, et al.
Publicado: (2020)

Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis
por: Tang, Fengjie, et al.
Publicado: (2020)

Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance
por: Radić, Martina, et al.
Publicado: (2022)

Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib
por: Lehraiki, Abdelali, et al.
Publicado: (2015)

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts
por: Kemper, Kristel, et al.
Publicado: (2015)

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo
por: Bonner, Michael Y., et al.
Publicado: (2016)

Role of Rho/MRTF in Aggressive Vemurafenib-Resistant Murine Melanomas and Immune Checkpoint Upregulation
por: Foda, Bardees M., et al.
Publicado: (2023)

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression
por: Michaelis, Martin, et al.
Publicado: (2014)

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
por: Castellani, Elisa, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ja7qrl305ee6ihu7nccln68b3i